Immunological targeting of cytomegalovirus for glioblastoma therapy

Human cytomegalovirus (CMV) is purportedly present in glioblastoma (GBM) while absent from the normal brain, making CMV antigens potentially ideal immunological anti-GBM targets. We recently demonstrated that patient-derived CMV pp65-specific T cells are capable of recognizing and killing autologous GBM tumor cells. This data supports CMV antigen-directed immunotherapies against GBM.

[1]  Katherine K. Matthews,et al.  Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma. , 2014, Cancer research.

[2]  S. Nair,et al.  Recognition and Killing of Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells , 2014, Clinical Cancer Research.

[3]  C. Cobbs.  Cytomegalovirus and brain tumor: epidemiology, biology and therapeutic aspects , 2013, Current opinion in oncology.

[4]  R. Khanna,et al.  Ex vivo functional analysis, expansion and adoptive transfer of cytomegalovirus‐specific T‐cells in patients with glioblastoma multiforme , 2012, Immunology and cell biology.

[5]  R. Grossman,et al.  Generation of Polyclonal CMV-specific T Cells for the Adoptive Immunotherapy of Glioblastoma , 2012, Journal of immunotherapy.

[6]  R. McLendon,et al.  Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. , 2008, Neuro-oncology.

[7]  S. Nair,et al.  RNA-transfected dendritic cells , 2002, Expert review of vaccines.

[8]  C. Cobbs,et al.  Human cytomegalovirus infection and expression in human malignant glioma. , 2002, Cancer research.

[9]  Eli Gilboa,et al.  Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. , 2000, Nature Medicine.

[10]  S. Nair,et al.  Isolation and Generation of Human Dendritic Cells , 1997, Current protocols in immunology.